LianBio Announces Clinical Supply Agreement With AstraZeneca In China To Evaluate BBP-398 Tn Combination With Osimertinib For Patients With Non-Small Cell Lung Cancer With EGFR Mutations
Portfolio Pulse from Benzinga Newsdesk
LianBio has announced a clinical supply agreement with AstraZeneca in China to evaluate BBP-398 in combination with Osimertinib for patients with non-small cell lung cancer with EGFR mutations.
July 12, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca has entered into a clinical supply agreement with LianBio in China, which could potentially expand the use of its drug Osimertinib.
The partnership with LianBio allows AstraZeneca to potentially expand the use of its drug Osimertinib in China. This could lead to increased sales and revenue for the company, hence the positive impact on the stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80